cytarabine and oxi 4503

cytarabine has been researched along with oxi 4503 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Beachamp, Z; Bossé, R; Brown, R; Cline, C; Cogle, CR; Collins, B; Hawkins, KE; Hiemenz, J; Hsu, J; May, WS; Moreb, JS; Norkin, M; Pettiford, LC; Turner, D; Uckun, F; Wingard, JR; Wise, E	1

Trials

1 trial(s) available for cytarabine and oxi 4503

Article	Year
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. British journal of haematology, 2020, Volume: 189, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diphosphates; Drug Resistance, Neoplasm; Drug Synergism; Feasibility Studies; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prodrugs; Respiratory Distress Syndrome; Salvage Therapy; Stilbenes; Treatment Outcome; Young Adult	2020

Article

Year

Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.

British journal of haematology, 2020, Volume: 189, Issue:5

Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diphosphates; Drug Resistance, Neoplasm; Drug Synergism; Feasibility Studies; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prodrugs; Respiratory Distress Syndrome; Salvage Therapy; Stilbenes; Treatment Outcome; Young Adult

2020